

## **GSK Hiberix approved by FDA**

The U.S. Food and Drug Administration says it has approved the vaccine **Hiberix** as a booster dose for children ages 15 months through 4 years. GSK will be adding this to the Child Health Advantage contract soon, so please keep an eye out for further communications regarding availability of this product.

The addition of this product provides physicians the opportunity to again deliver the 4<sup>th</sup> booster dose needed in the immunization schedule for Haemophilus influenzae Type b (Hib).

.....

The approval of Hiberix, a Haemophilus influenzae Type b vaccine, came following a nationwide shortage of Hib vaccines due to the recall and production suspension of two of four vaccines licensed in the United States for primary and booster Hib immunization, the FDA said in a release.

Although current vaccine supply is sufficient to begin catch-up vaccinations, the FDA said it is not yet ample enough to support mass vaccination of all children whose boosters were deferred.

To read more about the FDA approval of Hiberix, click [here](#).